Department of Gastroenterology, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan.
Esophagus. 2022 Jul;19(3):469-476. doi: 10.1007/s10388-022-00917-6. Epub 2022 Mar 23.
Patients with early esophageal squamous cell carcinoma (ESCC) may develop multiple second primary ESCC and cancers in other organs even after curative endoscopic resection (ER). We investigated whether administration of chemoradiotherapy (CRT) after ER decreases the incidence of second primary cancers.
We conducted a post hoc analysis of the prospective study. Among the registered 170 patients with clinical submucosal ESCC, 74 underwent ER alone, and 96 underwent ER followed by CRT (ER + CRT) because of pathological results of submucosal or lympho-vascular invasion. We compared the incidence of second primary cancers in esophagus and in other organs between two treatment groups. A univariate analysis was performed to investigate the related risk factors. All patients were followed up with esophagogastroduodenoscopy and CT every 4 months for the first 3 years and every 6 months thereafter.
Sixty-one ESCC were detected in 32 patients, and the 3-year cumulative incidence of multiple ESCCs was not different between ER + CRT and ER alone (10.4% vs. 13.5%). Sixty-three second primary cancers in other organs were detected in 45 patients, and there was no difference in the cumulative incidence between two groups. The risk factors for multiple ESCCs were high alcohol consumption and grade C multiple Lugol-voiding lesions. Heavy drinker or patients with grade C multiple Lugol-voiding lesion rather than CRT were at risk for second primary ESCC.
CRT after ER did not decrease the cumulative incidence of second primary ESCC nor cancers in other organs comparing with ER alone.
即使在根治性内镜切除(ER)后,早期食管鳞状细胞癌(ESCC)患者仍可能发生多发第二原发 ESCC 和其他器官的癌症。我们研究了 ER 后进行放化疗(CRT)是否会降低第二原发癌的发生率。
我们对前瞻性研究进行了事后分析。在登记的 170 例临床黏膜下 ESCC 患者中,74 例仅接受 ER 治疗,96 例因黏膜下或淋巴管侵犯的病理结果而接受 ER 联合 CRT(ER+CRT)治疗。我们比较了两组患者食管和其他器官第二原发癌的发生率。采用单因素分析探讨相关危险因素。所有患者均接受随访,前 3 年每 4 个月进行 1 次上消化道内镜和 CT 检查,此后每 6 个月进行 1 次。
32 例患者中发现 61 例 ESCC,ER+CRT 和 ER 组的 3 年多发性 ESCC 累积发生率无差异(10.4% vs. 13.5%)。45 例患者中发现 63 例其他器官的第二原发癌,两组累积发生率无差异。多发性 ESCC 的危险因素是大量饮酒和 C 级多发 Lugol 不染区。大量饮酒者或 C 级多发 Lugol 不染区患者而非 CRT 是发生第二原发 ESCC 的危险因素。
与 ER 相比,ER 后 CRT 并未降低第二原发 ESCC 或其他器官癌症的累积发生率。